Lorviqua 25 mg Film-Coated Tablets

Manufacturer
Pfizer Manufacturing Deutschland GmbH.(GERMANY)

Registraction Number
MAL20126003AZ

Content:
Lorviqua 25 mg Film-Coated Tablets contain 25 mg of lorlatinib and 1.58 mg of lactose monohydrate as an excipient. The tablets are round, light pink, and debossed with "Pfizer" on one side and "25" and "LLN" on the other side.
Indications:
Lorviqua is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). It can be used as a monotherapy in patients who have not been previously treated with an ALK inhibitor, or in patients whose disease has progressed after treatment with other ALK inhibitors such as alectinib, ceritinib, or crizotinib.
Instructions:

• Dosage: The recommended dose is 100 mg taken orally once daily. Treatment should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.
• Administration: Lorviqua can be taken with or without food. Tablets should be swallowed whole.
• Missed Doses: If a dose is missed, it should be taken as soon as the patient remembers, unless it is less than 4 hours before the next dose. In that case, the missed dose should be skipped.
• Dose Modifications: Dosing interruption or dose reduction may be required based on individual safety and tolerability. The first dose reduction is to 75 mg taken orally once daily.